Is non‑arteritic anterior ischemic optic neuropathy (NAION) a risk associated with glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) such as exenatide, liraglutide, dulaglutide, or semaglutide?

NAION Risk with GLP-1 Receptor Agonists: A Small but Real Association

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) are associated with a modest increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), but the absolute risk remains very low—approximately 0.09% over 18 months, translating to a number needed to harm of approximately 2,700-3,300 patients. This small risk should not routinely prevent prescribing these medications given their substantial cardiovascular, renal, and mortality benefits, but warrants informed consent and targeted monitoring in high-risk patients 1, 2, 3.

Understanding the Evidence

The most recent meta-analysis from 2026 pooled 15 longitudinal studies involving over 1.5 million patients and found an odds ratio of 1.70 (95% CI 1.23-2.36) for NAION with GLP-1 RA use 1. The absolute risk difference was only 0.037%, meaning you would need to treat approximately 2,700 patients to cause one additional case of NAION. Importantly, there was no association with overall ocular adverse events (OR 0.95), suggesting this is a specific rather than generalized ocular risk 1.

Multiple large observational studies support this finding. A Swedish nationwide cohort study found risks of 0.04% versus 0.02% at 1 year when comparing GLP-1 RAs to SGLT2 inhibitors 2. However, this difference was substantially attenuated in analyses restricted to patients on metformin (suggesting confounding by diabetes severity may partially explain the association) 2. A U.S. target trial emulation found an 18-month risk difference of 3.0 per 10,000 patients versus SGLT2 inhibitors and 3.6 per 10,000 versus DPP-4 inhibitors 3.

Critical nuance: The observed association may reflect residual confounding rather than direct causation. Patients prescribed GLP-1 RAs often have more severe diabetes, longer disease duration, and more cardiovascular risk factors—all independent risk factors for NAION. When studies better controlled for diabetes severity (such as restricting to metformin users), the risk differences diminished substantially 2.

Who Is at Highest Risk?

The risk is not uniform across all patients. NAION events occurred predominantly in:

• Men (70% of cases) 3
• Patients over age 50 (85% of cases) 3
• Those with pre-existing cardiovascular disease 3
• Patients with ophthalmic conditions 3
• Those on multiple diabetes medications (suggesting more severe disease) 3

Women and patients under 50 years showed minimal risk differences 3.

Clinical Management Algorithm

Before Starting GLP-1 RAs:

1. Assess baseline NAION risk factors:

   • Age >50 years, male sex
   • History of cardiovascular disease
   • Pre-existing ophthalmic conditions (especially diabetic retinopathy)
   • Small optic disc with crowded appearance (cup-to-disc ratio <0.3)
   • Obstructive sleep apnea, hypertension, hyperlipidemia

2. Ensure appropriate eye examination:

   • Patients should undergo guideline-recommended dilated eye examination if not done within the last 12 months 4
   • This is particularly important when intensifying glucose-lowering therapy, as rapid A1C reduction can worsen diabetic retinopathy 5, 6

3. Informed consent discussion:

   • Explain the very low absolute risk (approximately 1 in 2,700-3,300)
   • Emphasize the substantial proven benefits: cardiovascular risk reduction, mortality benefit, weight loss, and kidney protection
   • Discuss symptoms of NAION: sudden, painless vision loss in one eye, often noticed upon awakening

During Treatment:

1. Monitor for NAION symptoms:

   • Educate patients to report sudden, painless vision loss immediately
   • Symptoms include: sudden vision loss (often upon awakening), altitudinal visual field defects, relative afferent pupillary defect

2. Continue guideline-based retinopathy screening:

   • Annual dilated eye exams if any diabetic retinopathy is present 5, 6
   • Every 1-2 years if no retinopathy and glycemic control is good 5, 6
   • More frequent monitoring if retinopathy is progressing 5, 6

If NAION Develops:

1. Immediate ophthalmology referral for diagnostic confirmation and management
2. Consider discontinuation of GLP-1 RA in consultation with ophthalmology and endocrinology, weighing the cardiovascular/metabolic benefits against optic nerve risk
3. Evaluate the contralateral eye as NAION can be bilateral (though typically sequential)

Important Caveats

The diabetic retinopathy signal is distinct from NAION. GLP-1 RAs (particularly semaglutide and dulaglutide) have been associated with worsening diabetic retinopathy in randomized trials, but this appears related to rapid A1C reduction rather than a direct drug effect 5, 6. This is a known phenomenon with any therapy causing rapid glucose lowering (including insulin) and typically represents initial worsening before long-term benefit 5.

The FDA drug labels for semaglutide and dulaglutide warn about diabetic retinopathy complications but do not specifically mention NAION 7, 8. Semaglutide's label notes that in the SUSTAIN-6 trial, 3.0% of semaglutide patients versus 1.8% of placebo patients experienced diabetic retinopathy complications, with higher absolute risk in those with pre-existing retinopathy 8.

Do not withhold GLP-1 RAs based solely on NAION concerns. The cardiovascular, renal, and mortality benefits are substantial and well-established 9, 10. The absolute NAION risk is very small. The North American Neuro-Ophthalmology Society and American Academy of Ophthalmology consensus statement emphasizes that shared decision-making is appropriate, but the overall magnitude of risk remains low 11.

Bottom Line

NAION is a real but rare complication of GLP-1 RA therapy. The number needed to harm (approximately 2,700-3,300) is far higher than the number needed to treat for cardiovascular benefit. Use informed consent, ensure appropriate baseline eye examinations, educate patients about sudden vision loss symptoms, and maintain guideline-based retinopathy screening. The proven mortality and cardiovascular benefits of GLP-1 RAs generally outweigh this small optic nerve risk for most patients.